Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study

Screening for Prostate Cancer

(2018) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

(2018) Tokhir Dadaev et al.   Nature Communications

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts

(2018) Tyler M Seibert et al.   BMJ-British Medical Journal

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts

(2018) Tyler M Seibert et al.   BMJ-British Medical Journal

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer

(2018) Nora Pashayan et al.   JAMA Oncology

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis

(2018) Dragan Ilic et al.   BMJ-British Medical Journal

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

(2018) Marco Matejcic et al.   Nature Communications

Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms

(2016) Roman Gulati et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

(2016) Freddie C. Hamdy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)

(2016) Joanna C Thorn et al.   BMJ Open

Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies

(2016) Joshua A. Roth et al.   JAMA Oncology

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis

(2015) Nora Pashayan et al.   GENETICS IN MEDICINE

Estimating the cost of caring for people with cancer at the end of life: A modelling study

(2015) Jeff Round et al.   PALLIATIVE MEDICINE

Decomposing socio-economic inequality in colorectal cancer screening uptake in England

(2015) Francesca Solmi et al.   SOCIAL SCIENCE & MEDICINE

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

(2014) Fritz H Schröder et al.   LANCET

Public health implications from COGS and potential for risk stratification and screening

(2013) Hilary Burton et al.   NATURE GENETICS

The genetic epidemiology of prostate cancer and its clinical implications

(2013) Rosalind Eeles et al.   Nature Reviews Urology

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement

(2013) Don Husereau et al.   VALUE IN HEALTH

Quality-of-Life Effects of Prostate-Specific Antigen Screening

(2012) Eveline A.M. Heijnsdijk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England

(2011) Christian von Wagner et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Using Health State Utility Values from the General Population to Approximate Baselines in Decision Analytic Models when Condition-Specific Data are Not Available

(2011) Roberta Ara et al.   VALUE IN HEALTH

Mean sojourn time, overdiagnosis and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

(2009) N Pashayan et al.   BRITISH JOURNAL OF CANCER